GLP-1 Receptor Agonist Market Growth

High Unmet Needs in Obesity and Diabetes to Drive GLP-1 Receptor Agonist Market Growth; Anticipated to Cross USD 180 billion by 2035

According to a recently published report by Roots Analysis, the rising demand for GLP-1 receptor agonist market targeting type 2 diabetes and obesity has prompted researchers and drug developers to leverage their expertise and capabilities to expedite approvals of innovative and highly effective drugs. This focus on efficiency and innovation is driving the growth of the GLP-1 receptor agonist drugs market.

GLP-1 Receptor Agonist Market Drugs Industry Overview

The GLP-1 receptor agonist market size is estimated to reach over 180 billion by 2035, growing at a CAGR of 6.6% during the forecast period till 2035.

With over 150 GLP-1 receptor agonist drug candidate under evaluation across various stages of clinical development; it is safe to say that GLP-1 receptor agonist drugs candidates have demonstrated tremendous potential with an aim to treat metabolic disorders, including target disease indications such as obesity, type 2 diabetes and non-alcoholic steatohepatitis (NASH). Further, GLP-1 receptor agonist drugs are gaining popularity due to several reasons, including increased awareness among doctors and patients. Additionally, changes in people's habits, social media buzz, celebrity endorsements, and even direct-to-consumer advertising have contributed to the rising demand for GLP-1 receptor agonist drugs. In addition, extensive research efforts along with encouraging clinical trial results have led developers in supporting seamless transition from preclinical to clinical success. The aforementioned factors are likely to present lucrative market growth opportunities for drug developers and this domain is anticipated to have enormous growth in the coming years.

Browse 95+ figures and 125+ market data tables spread across 210+ pages and detailed Table of Content on “GLP-1 Receptor Agonist Market by Type of Molecule, Active Compound  Used, Type of GLP-1 Agonist Drug, Type of GLP-1 Agonist, Route of Administration, Target indication, Geography, Leading Drug Developers and Sales Forecast, Till 2035” here: https://www.rootsanalysis.com/reports/glp-1-market/request-sample.html

Market Drivers

Several factors are propelling the growth of the GLP-1 receptor agonist market. One of the key factors driving the future of GLP-1 receptor agonist market is the rising prevalence of metabolic disorders. Further, there has been a shift towards the development of oral forms of GLP-1 receptor agonist drugs (which are generally administered via injections), owing to their several benefits making GLP-1 receptor agonist therapies more accessible and convenient. In addition, the increasing preference for oral drug formulation over traditional drug delivery approaches for managing chronic diseases has become a primary growth factor driving the market during the forecast period.

Market Restraints

While the GLP-1 receptor agonist market is experiencing substantial growth, there are certain restraints that can hinder the growth of the industry. One of the primary factors includes growing interclass drug competition in this domain. Further, high treatment cost limits their accessibility. Additionally, despite the surge in demand of GLP-1 receptor agonist drugs manufacturing capacity of drug developers emerge as the major concern leading to supply shortages and delays in meeting the growing demand for these drugs and slowing market growth and patient access.

Growth Factors

Despite several challenges, various growth factors continue to propel the GLP-1 receptor agonist market forward. One notable factor is the expansion of developers' pipeline portfolios, which broadens treatment options. Additionally, integrating GLP-1 receptor agonist drugs with digital health technologies (such as mobile health applications, smart wearables, and telemedicine platforms) promises to revolutionize personalized medicine, thereby enhancing the treatment efficacy and improving medication adherence.

GLP-1 Receptor Agonist Market Segments 

Based on type of molecule, the market is segmented into biologics and small molecules

• The small molecules segment captures the largest revenue share of close to 55% in the GLP-1 receptor agonist, in 2024.
• The biologics segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 15% during the forecast period.

Based on active compound used, the market is segmented into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide¸ other active compounds

• The semaglutide segment captures the largest revenue share of close to 55% followed by tirzepatide (23%) in the GLP-1 receptor agonist market, in 2024.
• The survodutide and retatrutide segment is anticipated to witness the highest market growth rate of around 50% annually during the forecast period.

Based on type of GLP-1 agonist drug, the market is segmented into long-acting GLP-1 agonist and short-acting GLP-1 agonist

• The GLP-1 receptor agonist market is solely captured by dual-agonist segment, owing to the approval of only one short-acting GLP-1 agonist till date
• The short-acting GLP-1 agonist segment is anticipated to witness the highest market growth rate of around 54% annually during the forecast period.

Based on type of agonist, the market is segmented into single-agonist, dual-agonist and tri-agonist

• The single agonist segment captures the largest revenue share of 77% in the GLP-1 receptor agonist market, in 2024.
• The tri-agonist segment is anticipated to witness the highest market growth rate of around 48% annually during the forecast period.

Based on route of administration, the market is segmented into oral route and parenteral route

• The parenteral route of administration segment led the GLP-1 receptor agonist market, capturing the largest revenue in 2024.
• The oral segment is anticipated to witness the highest market growth rate of around 17% annually, during the forecast period.

Based on target indication, the market is segmented into Alzheimer’s disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes

• The type 2 Diabetes segment captures the largest revenue share of 75% in the GLP-1 receptor agonist market, in 2024.
• The non-alcoholic steatohepatitis (NASH) segment is anticipated to witness the highest market growth rate of around 50% annually during the forecast period.

Based on geographical regions, the market is segmented into North America, Europe, Latin America and Asia Pacific

• North America dominates the GLP-1 receptor agonist market and accounts for the majority (around 75%) of the market share, in 2024.
• In Asia-Pacific is anticipated to be the fastest growing segment in this industry, with an annualized rate of around 14.6%, during the forecast period.

Key Companies Profiled

The GLP-1 receptor agonist market report also includes detailed profiles of key players (listed below) that are involved in development of GLP-1 receptor agonist drugs:

• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/glp-1-market/request-sample.html

About Roots Analysis

Roots Analysis is a global life sciences market research, competitive intelligence, and strategic consulting firm specializing in the pharmaceutical, biotechnology, medical devices and healthcare industries. Founded in 2013, we have served 1,500+ global clients, from startups to Fortune 500 companies, helping them evaluate market opportunities, assess competition, and make data-driven business decisions. We also provide dedicated solutions to academic institutes, universities, non-profit organizations and other non-industry players.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com